Liposarcoma clinical trials at UC Cancer

• Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

  open to eligible people ages 18 years and up

  This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.

  at UCLA

Last updated: November 4, 2020